German draft offers firms pro and cons
Positive measures including a drive to increase uptake of biosimilars are offset by more negative aspects, such as promoting pharmacy substitution of biologics and exposing cytostatic cancer therapies to tender processes, under draft medicines legislation unveiled by Germany’s ministry of health.
You may also be interested in...
Battle-Lines Built Up On Biologic Substitution In Germany
German legislators are faced with entrenched positions on pharmacy-level switching of biologic drugs as they consider draft legislation. Industry is united in opposing the proposal.
Germany Could Introduce Biosimilar Substitution By Pharmacists In Three Years
A German bill aims to cut spending on biologics, but new revisions mean that measures on biosimilar substitution are likely to be delayed by three years.
Germany Rows Back On Plans For Biosimilar Substitution
Plans to allow German pharmacists to substitute biological drugs in the same way as they do small-molecule medicines have been watered down in the latest draft of healthcare reforms.